Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

The treatment scenario for newly‐diagnosed transplant‐ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors and/or immunomodulatory drugs +/− the monoclonal antibody Daratumumab are used for first‐line treatment, even if head‐to‐head compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Botta, Cirino, Gigliotta, Emilia, Paiva, Bruno, Anselmo, Rita, Santoro, Marco, Otero, Paula Rodriguez, Carlisi, Melania, Conticello, Concetta, Romano, Alessandra, Solimando, Antonio Giovanni, Cerchione, Claudio, Vià, Matteo Da, Bolli, Niccolò, Correale, Pierpaolo, Di Raimondo, Francesco, Gentile, Massimo, San Miguel, Jesus, Siragusa, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084226/
https://www.ncbi.nlm.nih.gov/pubmed/35794705
http://dx.doi.org/10.1002/hon.3041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084226/
https://www.ncbi.nlm.nih.gov/pubmed/35794705
http://dx.doi.org/10.1002/hon.3041

Ejemplares similares